Biogen Idec announced the company submitted a Biologics License Application (BLA) to the FDA for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. rFIXFc is a clotting factor developed using proprietary monomeric Fc fusion technology, which makes use of a naturally occurring pathway that delays the destruction of factor and cycles it back into the bloodstream, resulting in a longer circulating half-life.

The regulatory submission was based on results from B-LONG, a registrational Phase 3 clinical study of patients with hemophilia B.

For more information visit